Cobalt and GlaxoSmithKline Finally Reach Settlement

It was announced on 15 November 2006 that Cobalt Laboratories Inc. has reached a patent litigation settlement with GlaxoSmithKline Plc. regarding its ‘sumatriptan succinate tablets’, the generic version of GlaxoSmithKline’s Imitrex, which is sold to treat migraine pain.

Cobalt Pharmaceuticals Inc. announced in a statement that the company may distribute a generic version in the U.S. by the first quarter of 2009 following the settlement which remains subject to government review.

This was just one term that was agreed between lawyers, but the statement did not provide additional details on the other terms of the settlement.

share this Article

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on email

Recent Articles

How are NFT’s regulated in the UK?

The Financial Conduct Authority (FCA) has not yet provided guidance on NFT’s specifically with regards to regulation in the United Kingdom (UK). However, the FCA